245 related articles for article (PubMed ID: 32217758)
41. PD-1 blockade attenuates immunosuppressive myeloid cells due to inhibition of CD47/SIRPα axis in HPV negative head and neck squamous cell carcinoma.
Yu GT; Bu LL; Huang CF; Zhang WF; Chen WJ; Gutkind JS; Kulkarni AB; Sun ZJ
Oncotarget; 2015 Dec; 6(39):42067-80. PubMed ID: 26573233
[TBL] [Abstract][Full Text] [Related]
42. Tumor Mutation Burden, Immune Cell Infiltration, and Construction of Immune-Related Genes Prognostic Model in Head and Neck Cancer.
Jiang AM; Ren MD; Liu N; Gao H; Wang JJ; Zheng XQ; Fu X; Liang X; Ruan ZP; Tian T; Yao Y
Int J Med Sci; 2021; 18(1):226-238. PubMed ID: 33390791
[No Abstract] [Full Text] [Related]
43. CXCR6 deficiency impairs cancer vaccine efficacy and CD8
Karaki S; Blanc C; Tran T; Galy-Fauroux I; Mougel A; Dransart E; Anson M; Tanchot C; Paolini L; Gruel N; Gibault L; Lepimpec-Barhes F; Fabre E; Benhamouda N; Badoual C; Damotte D; Donnadieu E; Kobold S; Mami-Chouaib F; Golub R; Johannes L; Tartour E
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33692218
[TBL] [Abstract][Full Text] [Related]
44. Inflammation-induced myeloid-derived suppressor cells associated with squamous cell carcinoma of the head and neck.
Chen WC; Lai CH; Chuang HC; Lin PY; Chen MF
Head Neck; 2017 Feb; 39(2):347-355. PubMed ID: 27696591
[TBL] [Abstract][Full Text] [Related]
45. The prognosis of head and neck squamous cell carcinoma related to immunosuppressive tumor microenvironment regulated by IL-6 signaling.
Tsai MS; Chen WC; Lu CH; Chen MF
Oral Oncol; 2019 Apr; 91():47-55. PubMed ID: 30926062
[TBL] [Abstract][Full Text] [Related]
46. Establishment and validation of immune microenvironmental gene signatures for predicting prognosis in patients with head and neck squamous cell carcinoma.
Wang J; Tian Y; Zhu G; Li Z; Wu Z; Wei G; Zhuang L; Li Z; Chen X; Zhang X; Zheng J; Cai G
Int Immunopharmacol; 2021 Aug; 97():107817. PubMed ID: 34091115
[TBL] [Abstract][Full Text] [Related]
47. STAT1 inhibits T-cell exhaustion and myeloid derived suppressor cell accumulation to promote antitumor immune responses in head and neck squamous cell carcinoma.
Ryan N; Anderson K; Volpedo G; Hamza O; Varikuti S; Satoskar AR; Oghumu S
Int J Cancer; 2020 Mar; 146(6):1717-1729. PubMed ID: 31709529
[TBL] [Abstract][Full Text] [Related]
48. Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor.
Curti BD; Koguchi Y; Leidner RS; Rolig AS; Sturgill ER; Sun Z; Wu Y; Rajamanickam V; Bernard B; Hilgart-Martiszus I; Fountain CB; Morris G; Iwamoto N; Shimada T; Chang S; Traber PG; Zomer E; Horton JR; Shlevin H; Redmond WL
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33837055
[TBL] [Abstract][Full Text] [Related]
49. High Abundance of Intratumoral γδ T Cells Favors a Better Prognosis in Head and Neck Squamous Cell Carcinoma: A Bioinformatic Analysis.
Lu H; Dai W; Guo J; Wang D; Wen S; Yang L; Lin D; Xie W; Wen L; Fang J; Wang Z
Front Immunol; 2020; 11():573920. PubMed ID: 33101298
[TBL] [Abstract][Full Text] [Related]
50. A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma.
Kim CG; Hong MH; Kim D; Lee BH; Kim H; Ock CY; Kelly G; Bang YJ; Kim G; Lee JE; Kim C; Kim SH; Hong HJ; Park YM; Sim NS; Park H; Park JW; Lee CG; Kim KH; Park G; Jung I; Han D; Kim JH; Cha J; Lee I; Kang M; Song H; Oum C; Kim S; Kim S; Lim Y; Kim-Schulze S; Merad M; Yoon SO; Kim HJ; Koh YW; Kim HR
Clin Cancer Res; 2024 May; 30(10):2097-2110. PubMed ID: 38457288
[TBL] [Abstract][Full Text] [Related]
51. Intratumoral STING activations overcome negative impact of cisplatin on antitumor immunity by inflaming tumor microenvironment in squamous cell carcinoma.
Harabuchi S; Kosaka A; Yajima Y; Nagata M; Hayashi R; Kumai T; Ohara K; Nagato T; Oikawa K; Ohara M; Harabuchi Y; Ohkuri T; Kobayashi H
Biochem Biophys Res Commun; 2020 Feb; 522(2):408-414. PubMed ID: 31771883
[TBL] [Abstract][Full Text] [Related]
52. Blockage of the NLRP3 inflammasome by MCC950 improves anti-tumor immune responses in head and neck squamous cell carcinoma.
Chen L; Huang CF; Li YC; Deng WW; Mao L; Wu L; Zhang WF; Zhang L; Sun ZJ
Cell Mol Life Sci; 2018 Jun; 75(11):2045-2058. PubMed ID: 29184980
[TBL] [Abstract][Full Text] [Related]
53. Prognostic impact of immune microenvironment in laryngeal and pharyngeal squamous cell carcinoma: Immune cell subtypes, immuno-suppressive pathways and clinicopathologic characteristics.
Karpathiou G; Casteillo F; Giroult JB; Forest F; Fournel P; Monaya A; Froudarakis M; Dumollard JM; Prades JM; Peoc'h M
Oncotarget; 2017 Mar; 8(12):19310-19322. PubMed ID: 28038471
[TBL] [Abstract][Full Text] [Related]
54. Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma.
Espinosa-Cotton M; Rodman Iii SN; Ross KA; Jensen IJ; Sangodeyi-Miller K; McLaren AJ; Dahl RA; Gibson-Corley KN; Koch AT; Fu YX; Badovinac VP; Laux D; Narasimhan B; Simons AL
J Immunother Cancer; 2019 Mar; 7(1):79. PubMed ID: 30890189
[TBL] [Abstract][Full Text] [Related]
55. The Immune Infiltration in HNSCC and Its Clinical Value: A Comprehensive Study Based on the TCGA and GEO Databases.
Sun X; Zhang L; Liu S
Comput Math Methods Med; 2021; 2021():1163250. PubMed ID: 34790249
[TBL] [Abstract][Full Text] [Related]
56. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
Yang WF; Wong MCM; Thomson PJ; Li KY; Su YX
Oral Oncol; 2018 Nov; 86():81-90. PubMed ID: 30409325
[TBL] [Abstract][Full Text] [Related]
57. High expression of CLEC10A in head and neck squamous cell carcinoma indicates favorable prognosis and high-level immune infiltration status.
Zou M; Wu H; Zhou M; Xiao F; Abudushalamu G; Yao Y; Zhao F; Gao W; Yan X; Fan X; Wu G
Cell Immunol; 2022 Feb; 372():104472. PubMed ID: 35093731
[TBL] [Abstract][Full Text] [Related]
58. γ-Secretase inhibitor reduces immunosuppressive cells and enhances tumour immunity in head and neck squamous cell carcinoma.
Mao L; Zhao ZL; Yu GT; Wu L; Deng WW; Li YC; Liu JF; Bu LL; Liu B; Kulkarni AB; Zhang WF; Zhang L; Sun ZJ
Int J Cancer; 2018 Mar; 142(5):999-1009. PubMed ID: 29047105
[TBL] [Abstract][Full Text] [Related]
59. Targeting CMTM6 Suppresses Stem Cell-Like Properties and Enhances Antitumor Immunity in Head and Neck Squamous Cell Carcinoma.
Chen L; Yang QC; Li YC; Yang LL; Liu JF; Li H; Xiao Y; Bu LL; Zhang WF; Sun ZJ
Cancer Immunol Res; 2020 Feb; 8(2):179-191. PubMed ID: 31771985
[TBL] [Abstract][Full Text] [Related]
60. Characteristics and impact of programmed death-ligand 1 expression, CD8+ tumor-infiltrating lymphocytes, and p16 status in head and neck squamous cell carcinoma.
Ngamphaiboon N; Chureemas T; Siripoon T; Arsa L; Trachu N; Jiarpinitnun C; Pattaranutaporn P; Sirachainan E; Larbcharoensub N
Med Oncol; 2019 Jan; 36(2):21. PubMed ID: 30666437
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
